Charles River Laboratories (CRL) Tops Q4 EPS by 10c, Guides FY17 EPS In-Line
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $280.76 -2.68%
Revenue Growth %: -4.3%
Financial Fact:
Net sales related to services: 292.85M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -4.3%
Financial Fact:
Net sales related to services: 292.85M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $1.21, $0.10 better than the analyst estimate of $1.11. Revenue for the quarter came in at $466.8 million versus the consensus estimate of $441.64 million.
GUIDANCE:
Charles River Laboratories sees FY2017 EPS of $5.00-$5.10, versus the consensus of $5.05.
|
|
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- Mission Produce (AVO) Misses Q3 EPS by 2c; offers outlook
- BMO Capital Starts Abercrombie & Fitch (anf) at Outperform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
